Products for Research Use Only

VHL Antibody

CAT: 0223-13-158Size: 100 µLDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0223-13-158Size:100 µL
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Background
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
NCBI Gene ID
7428
Swiss Prot
P40337
Host
Rabbit
Reactivity
Human, Mouse, Rat
Immunogen
Recombinant fusion protein containing a sequence corresponding to amino acids 1-172 of human VHL (NP_937799.1) .
Clonality
Polyclonal
Conjugation
Unconjugated
Type
Primary Antibodies
Field of Research
Apoptosis, Cancer, Cell Cycle, Immunology
Purification
Affinity purification
Positive Control
HeLa
Concentration
Batch dependent
Buffer
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Store at -20˚ C. Avoid freeze / thaw cycles.
Calculated Molecular Weight
Observed: 24kDa
Fragment
IgG
Symbol
VHL
Positive Control 2
Mouse brain
Positive Control 3
Rat brain
NCBI Official Name
Von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase
NCBI Organism
Homo sapiens
Other Product Names
VHL, von Hippel-Lindau tumor suppressor, HRCA1, RCA1, VHL1, elongin binding protein, von Hippel-Lindau syndrome, pVHL
Tested Applications
WB, IF
Physical Properties
Liquid